Replies to post #23933 on Mymetics Corp (MYMX)

[Work Harder]

Highlights

•
Engineered yeast-expressed SARS-CoV-2 RBD, RBD219-N1C1, prevents oligomerization and improves stability.

•
The engineering does not impact protein structure and functionality.

•
The engineering improves the fermentation yield.

•
RBD219-N1C1 can be purified with a simple purification scheme.

https://www.sciencedirect.com/science/article/pii/S0304416521000519?via%3Dihub

https://www.researchgate.net/publication/350066928_Genetic_modification_to_design_a_stable_yeast-expressed_recombinant_SARS-CoV-2_receptor_binding_domain_as_a_COVID-19_vaccine_candidate

Pre-Clinical Testing Unit

Unit Director - Kathryn Jones, D.V.M., Ph.D.
Research Coordinator - Brian Keegan

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162837055

Ana Carolina Leão

Federal University of Minas Gerais
Departamento de ParasitologiaBelo Horizonte, Brazil

https://www.researchgate.net/profile/Ana-Leao-3

Bailing Zhan

University of Toronto | U of T · Department of Geography at Mississauga

https://www.researchgate.net/profile/Bailing-Zhan